TY - JOUR
T1 - ALSUntangled #77
T2 - Psilocybin
AU - Bakshi, Bhavya
AU - Yerraguntla, Sandeep
AU - Armon, Carmel
AU - Barkhaus, Paul
AU - Bertorini, Tulio
AU - Bowser, Robert
AU - Breevoort, Sarah
AU - Bromberg, Mark
AU - Brown, Andrew
AU - Carter, Gregory T.
AU - Chang, Vincent
AU - Crayle, Jesse
AU - Fullam, Timothy
AU - Greene, Maxwell
AU - Heiman-Patterson, Terry
AU - Jackson, Carlayne
AU - Jhooty, Sartaj
AU - Mallon, Elise
AU - Cadavid, Javier Mascias
AU - Mcdermott, Christopher J.
AU - Pattee, Gary
AU - Pierce, Kaitlyn
AU - Ratner, Dylan
AU - Sun, Yuyao
AU - Wang, Olivia
AU - Wicks, Paul
AU - Wiedau, Martina
AU - Bedlack, Richard
N1 - Publisher Copyright:
© 2024 World Federation of Neurology on behalf of the Research Group on Motor Neuron Diseases.
PY - 2025
Y1 - 2025
N2 - ALSUntangled reviews alternate and off-label treatments prompted by patient interest. Here, we review psilocybin, a chemical derived from mushrooms and belonging in the category of drugs known as psychedelics. Psilocybin has plausible mechanisms for slowing ALS progression because of its ability to cross the blood brain barrier and effect neurogenesis and inflammation. Currently, there are no pre-clinical ALS models, case reports, or trials for psilocybin and ALS in the context of disease modifying therapy. Depending on dosing, there can be a high risk of psychological side effects including hallucinations and physical harm. Based on the above information, we do not currently support the use of psilocybin as a means to slow ALS progression.
AB - ALSUntangled reviews alternate and off-label treatments prompted by patient interest. Here, we review psilocybin, a chemical derived from mushrooms and belonging in the category of drugs known as psychedelics. Psilocybin has plausible mechanisms for slowing ALS progression because of its ability to cross the blood brain barrier and effect neurogenesis and inflammation. Currently, there are no pre-clinical ALS models, case reports, or trials for psilocybin and ALS in the context of disease modifying therapy. Depending on dosing, there can be a high risk of psychological side effects including hallucinations and physical harm. Based on the above information, we do not currently support the use of psilocybin as a means to slow ALS progression.
KW - Psilocybin
KW - inflammation
KW - neurogenesis
KW - psychedelics
UR - https://www.scopus.com/pages/publications/85212684507
UR - https://www.scopus.com/pages/publications/85212684507#tab=citedBy
U2 - 10.1080/21678421.2024.2441274
DO - 10.1080/21678421.2024.2441274
M3 - Article
C2 - 39709547
AN - SCOPUS:85212684507
SN - 2167-8421
VL - 26
SP - 385
EP - 388
JO - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
JF - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
IS - 3-4
ER -